Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165604 | 1.00 | SLC29A1 (0.48) | SLC29A1HIF1ATP53CYP3A4ABCC4 | |
| SCHEMBL13239695 | 0.91 | HIF1A (0.43) | SLC29A1HIF1AHPGD | |
| SCHEMBL15165603 | 0.86 | HPGD (0.43) | SLC29A1HIF1AHPGD | |
| SCHEMBL13239681 | 0.86 | HPGD (0.43) | SLC29A1HIF1AHPGD | |
| SCHEMBL13239688 | 0.84 | SLC29A1 (0.46) | SLC29A1HIF1ATP53CYP3A4ABCC4 | |
| SCHEMBL15165605 | 0.84 | SLC29A1 (0.46) | SLC29A1HIF1ATP53CYP3A4ABCC4 | |
| SCHEMBL15165611 | 0.84 | DNPH1 (0.40) | SLC29A1HIF1AHPGD | |
| SCHEMBL13239673 | 0.80 | HIF1A (0.46) | SLC29A1HIF1A | |
| SCHEMBL15165599 | 0.80 | HIF1A (0.46) | SLC29A1HIF1A | |
| SCHEMBL13239672 | 0.80 | HIF1A (0.46) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | SLC29A1 19/4885HIF1A 3959/4885TP53 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.